WallStreetZenWallStreetZen

NASDAQ: EIKN
Eikon Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for EIKN

Based on 1 analyst offering 12 month price targets for Eikon Therapeutics Inc

Min Forecast
$4.00-45.43%
Avg Forecast
$4.00-45.43%
Max Forecast
$4.00-45.43%

Should I buy or sell EIKN stock?

Based on 1 analyst offering ratings for Eikon Therapeutics Inc.

Sell
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
1 analysts 100%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Sell" rating. Learn More

Be the first to know when Wall Street analysts revise their EIKN stock forecasts and price targets.

EIKN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14

1 of 1

Forecast return on equity

Is EIKN forecast to generate an efficient return?

Company
-67.51%
Industry
21.83%
Market
168.15%
EIKN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is EIKN forecast to generate an efficient return on assets?

Company
-40.4%
Industry
23.8%
EIKN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

EIKN earnings per share forecast

What is EIKN's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$7.22
Avg 2 year Forecast
-$7.22
Avg 3 year Forecast
-$6.45

EIKN revenue forecast

What is EIKN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

EIKN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EIKN$7.33$4.00-45.43%Sell
TTRX$13.33$17.00+27.53%Buy
ZURA$4.11$21.00+410.95%Strong Buy
GALT$3.90$11.00+182.05%Buy
EDIT$2.62$4.50+71.76%Strong Buy
View Top Biotech Stocks

Eikon Therapeutics Stock Forecast FAQ

Is Eikon Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: EIKN) stock is to Sell EIKN stock.

Out of 1 analyst, 0 (0%) are recommending EIKN as a Strong Buy, 0 (0%) are recommending EIKN as a Buy, 0 (0%) are recommending EIKN as a Hold, 1 (100%) are recommending EIKN as a Sell, and 0 (0%) are recommending EIKN as a Strong Sell.

If you're new to stock investing, here's how to buy Eikon Therapeutics stock.

What is EIKN's earnings growth forecast for 2026-2028?

(NASDAQ: EIKN) Eikon Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.53%.

Eikon Therapeutics's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast EIKN's earnings for 2026 to be -$391,028,185, with the lowest EIKN earnings forecast at -$407,667,682, and the highest EIKN earnings forecast at -$333,277,430. On average, 8 Wall Street analysts forecast EIKN's earnings for 2027 to be -$391,185,263, with the lowest EIKN earnings forecast at -$447,478,979, and the highest EIKN earnings forecast at -$330,433,766.

In 2028, EIKN is forecast to generate -$349,613,603 in earnings, with the lowest earnings forecast at -$436,862,633 and the highest earnings forecast at -$290,622,468.

What is EIKN's revenue growth forecast for 2026-2028?

(NASDAQ: EIKN) Eikon Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.51%.

Eikon Therapeutics's revenue in 2026 is N/A.On average, 8 Wall Street analysts forecast EIKN's revenue for 2026 to be $0, with the lowest EIKN revenue forecast at $0, and the highest EIKN revenue forecast at $0. On average, 8 Wall Street analysts forecast EIKN's revenue for 2027 to be $0, with the lowest EIKN revenue forecast at $0, and the highest EIKN revenue forecast at $0.

In 2028, EIKN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is EIKN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: EIKN) forecast ROA is -40.4%, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is EIKN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year EIKN price target, the average EIKN price target is $4.00, with the highest EIKN stock price forecast at $4.00 and the lowest EIKN stock price forecast at $4.00.

The Wall Street analyst predicted that Eikon Therapeutics's share price could fall to $4.00 by Aug 14, 2027. The average Eikon Therapeutics stock price prediction forecasts a potential downside of 45.43% from the current EIKN share price of $7.33.

What is EIKN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: EIKN) Eikon Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that EIKN's EPS will be -$7.22 for 2026, with the lowest EPS forecast at -$7.53, and the highest EPS forecast at -$6.15. On average, analysts forecast that EIKN's EPS will be -$7.22 for 2027, with the lowest EPS forecast at -$8.26, and the highest EPS forecast at -$6.10. In 2028, EIKN's EPS is forecast to hit -$6.45 (min: -$8.07, max: -$5.37).

What is EIKN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: EIKN) forecast ROE is -67.51%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.